Targeted Oncology Staff

The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.

A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.

The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.

The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.

Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.

In the phase 3 EMBER-3 trial, imlunestrant plus abemaciclib doubled median progression-free survival vs imlunestrant alone in ESR1-mutated advanced breast cancer.

During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.

Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.

The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.

During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.

The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.

The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.

The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.

Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.

The approval of lutetium Lu 177 dotatate injection for GEP-NETs is based on results from the ERASMUS study.

First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.

SERENA-4 missed its PFS end point for camizestrant plus palbociclib vs anastrozole plus palbociclib in untreated advanced breast cancer.

The FDA has approved Pixclara (floretyrosine F 18), the first FET-PET imaging agent for distinguishing recurrent glioma from treatment-related change.

The FDA approved a label update cutting postinfusion monitoring for the first 2 tarlatamab doses from up to 24 hours down to 6 to 8 hours.

A new NCCN survey found all responding cancer centers report at least one anti-cancer drug shortage, with 94% short on ifosfamide and 71% on carboplatin.

During a live event, Seth M. Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice between systemic therapies for recurrent diffuse tenosynovial giant cell tumor.

The phase 2 RESTORE-PV trial is exploring the monoclonal antibody DISC-3405 in polycythemia vera across 2 dosing cohorts.

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

Scaling back thyroid ultrasonography referrals may meaningfully reduce diagnoses without affecting survival.

The FDA granted accelerated approval to sevabertinib for HER2-mutant, nonsquamous NSCLC regardless of prior systemic therapy, based on SOHO-01 trial data.

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how anemia and thrombocytopenia in extensive-stage small cell lung cancer are still managed one lineage, and one crisis, at a time.

DeLLphi-305 data show tarlatamab plus durvalumab significantly improved overall survival as first-line maintenance in extensive stage small cell lung cancer.

The FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify eligible patients for the camizestrant regimen.

The study also identified a link between early fatigue and eventual response to CAR T.